{'fraction_non_alphanumeric': 0.02034084661902144, 'fraction_numerical': 0.0021990104452996153, 'mean_word_length': 5.363636363636363, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Bortezomib - First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature.

BACKGROUND
Bortezomib is reversible inhibitor of proteasome proteins for mammalian cells. Bortezomib is proven to be cytotoxic to a number of tumor cells by disrupting their normal homeostatic mechanism and thereby causing cell death. Currently, Bortezomib is prescribed for patients with multiple myeloma and mantle cell lymphoma.


OBJECTIVE
This assessment highlights the overview of recent patents of Bortezomib. This review includes patents grouped in sections like product patents, process patent, composition related patents as well as treatment methodology. Objective of this article is to facilitate researchers with all existing patents at single place.


METHODS
Data were searched from various online databases. In which, paid databases include SciFinder® and Orbit® . Free databases include Patentscope® (WIPO), Worldwide Espacenet® (EPO), Google Patents and InPASS (Indian patent database).


RESULTS
Several new processes and composition related patents of Bortezomib have been recently patented as its orangebook listed patents are going to soon expire during July 2022. Further, due to problem of oxidation during development and long-term storage of Bortezomib formulation, a number of excipients are tried in these patents to stabilize the same. However, there is still need for further development of improved formulation of Bortezomib with better characteristics.


CONCLUSION
Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices.